Xeris Biopharma Holdings Inc

NASDAQ:XERS  
2.24
-0.02 (-0.88%)
Products

Xeris Biopharma Announces FDA Approval Of Cushing's Syndrome Treatment

Published: 12/30/2021 21:44 GMT
Xeris Biopharma Holdings Inc (XERS) - Xeris Biopharma Announces U.S. FDA Approval of Recorlev® (levoketoconazole) for the Treatment of Endogenous Hypercortisolemia in Adult Patients With Cushing’s Syndrome.
Xeris Biopharma Holdings Inc - Commercial Launch of Recorlev is Planned for Q1 2022.
Xeris Biopharma Holdings Inc - Approval of Recorlev Includes Boxed Warning for Hepatotoxicity and Qt Prolongation.